News >

Brentuximab Vedotin Combos Among Key Advances in Hodgkin, T-Cell Lymphoma

Jessica Hergert
Published: Tuesday, Dec 03, 2019

Alison J. Moskowitz, MD, clinical director of the Lymphoma Inpatient Unit at Memorial Sloan Kettering Cancer Center

Alison J. Moskowitz, MD

Following separate indications of brentuximab vedotin (Adcetris) for the treatment of patients with Hodgkin and T-cell lymphoma, investigators are continuing to dissect the role of the antibody-drug conjugate within each of these paradigms, said Alison J. Moskowitz, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication